FRI0195 EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY

Lupus Erythematosus ◽

Controlled Study ◽

Efficacy And Safety ◽

FRI0303 Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

10.1136/annrheumdis-2018-eular.1734 ◽

2018 ◽

Author(s):

R. van Vollenhoven ◽

B.H. Hahn ◽

G.C. Tsokos ◽

C. Wagner ◽

P. Lipsky ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

10.1136/lupus-2018-abstract.45 ◽

2018 ◽

Cited By ~ 1

Author(s):

R van Vollenhoven ◽

B Hahn ◽

G Tsokos ◽

C Wagner ◽

P Lipsky ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Interleukin 12 ◽

Phase 2 ◽

Efficacy And Safety ◽

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

The Lancet ◽

10.1016/s0140-6736(18)32167-6 ◽

2018 ◽

Vol 392 (10155) ◽

pp. 1330-1339 ◽

Cited By ~ 113

Author(s):

Ronald F van Vollenhoven ◽

Bevra H Hahn ◽

George C Tsokos ◽

Carrie L Wagner ◽

Peter Lipsky ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Randomised Controlled Study ◽

Randomised Controlled

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Case Medical Research ◽

10.31525/ct1-nct04058028 ◽

2019 ◽

Author(s):

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Faculty Opinions recommendation of Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8909956.9465054 ◽

2011 ◽

Author(s):

David Kluth ◽

Neeraj Dhaun

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Arthritis & Rheumatology ◽

10.1002/art.39856 ◽

2017 ◽

Vol 69 (2) ◽

pp. 362-375 ◽

Cited By ~ 78

Author(s):

Megan E. B. Clowse ◽

Daniel J. Wallace ◽

Richard A. Furie ◽

Michelle A. Petri ◽

Marilyn C. Pike ◽

...

Keyword(s):

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

FRI0183 STUDY DESIGN FOR A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE MODERATE-DOSE CORTICOSTEROIDS

10.1136/annrheumdis-2019-eular.5707 ◽

2019 ◽

Author(s):

Anca Askanase ◽

Enxu Zhao ◽

Julie Zhu ◽

Erin Connolly-Strong ◽

Richard Furie

Keyword(s):

Study Design ◽

Lupus Erythematosus ◽

Controlled Study ◽

Efficacy And Safety ◽

Moderate Dose ◽

Systemic Lupus ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725768310.793547377 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

Arthritis & Rheumatology ◽

10.1002/art.40049 ◽

2017 ◽

Vol 69 (5) ◽

pp. 1016-1027 ◽

Cited By ~ 98

Author(s):

William Stohl ◽

Andreas Schwarting ◽

Masato Okada ◽

Morton Scheinberg ◽

Andrea Doria ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽